Drug intelligence / Profile preview

GRN1005 + trastuzumab

Development stage: Unknown
Lead developer: Geron
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GRN1005 + trastuzumab is an experimental combination therapy consisting of GRN1005, a peptide-drug conjugate, and trastuzumab, a monoclonal antibody targeting HER2. GRN1005 is designed to deliver paclitaxel across the blood-brain barrier by targeting low-density lipoprotein receptor-related protein-1 (LRP-1), allowing it to treat brain metastases. Trastuzumab is a HER2 inhibitor used as standard-of-care in HER2-positive breast cancer. The combination is investigated primarily for HER2-positive metastatic breast cancer patients with brain metastases, aiming to improve delivery and cytotoxic effects within the brain[1][3][4][6][7][8].

Brand names: Herceptin
Other names: paclitaxel trevatide + trastuzumabpaclitaxel-Angiopep-2 conjugate + trastuzumabHerceptin + GRN1005

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)LRP1 (Prolow-density lipoprotein receptor-related protein 1)Microtubule

Beyond the preview

Go deeper on GRN1005 + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GRN1005 + trastuzumab.

Explore the full profile